An Orally Active Bradykinin B₁Receptor Antagonist Engineered as a Bifunctional Chimera of Sunflower Trypsin Inhibitor

An Orally Active Bradykinin B₁Receptor Antagonist Engineered as a Bifunctional Chimera of Sunflower Trypsin Inhibitor Unique Overlap in the Prerequisites for Thrombin Inhibition and Oral Bioavailability Resulting in Potent Oral Antithrombotics Improving Metabolic Stability by Glycosylation: Bifunctional Peptide Derivatives That Are Opioid Receptor Agonists and Neurokinin 1 Receptor Antagonists Potent, Efficacious, and Stable Cyclic Opioid Peptides with Long Lasting Antinociceptive Effect after Peripheral Administration Design of enkephalin modifications protected from brain extracellular peptidases providing long-term analgesia Novel Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) from Natural Product Anabaenopeptin Isolation, Co-Crystallization and Structure-Based Characterization of Anabaenopeptins as Highly Potent Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) Isolation, Co-Crystallization and Structure-Based Characterization of Anabaenopeptins as Highly Potent Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) Synthesis and receptor binding properties of chimeric peptides containing a μ-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide Synthesis and Structure−Activity Relationships of an Orally Available and Long-Acting Analgesic Peptide,N^α-Amidino-Tyr-<scp>d</scp>-Arg-Phe-MeβAla-OH (ADAMB)